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Different Leishmania species rely to different extents on abundant glycoconjugates, such as lipophosphogly-
can (LPG) and related molecules, in mammalian infections. Previously, we showed that Leishmania major
deletion mutants lacking the Golgi GDP-mannose transporter LPG2, which is required for assembly of the
dominant phosphoglycan (PG) repeats of LPG, were unable to survive in macrophages. These lpg2
 mutants,
however, retained the ability to generate asymptomatic, persistent infections in mice. In contrast, Ilg and
colleagues showed that Leishmania mexicana LPG2 mutants retained virulence for mice. Here we identiﬁed a
partial revertant population of the L. major lpg2
 mutants (designated lpg2
REV) that had regained the ability
to replicate in macrophages and induce disease pathology through a compensatory change. Like the lpg2
parent, the lpg2
REV revertant was unable to synthesize LPG2-dependent PGs in the promastigote stage and
thus remained highly attenuated in the ability to induce infection. However, after considerable delay lpg2
REV
revertant-infected mice exhibited lesions, and amastigotes isolated from these lesions were able to replicate
within macrophages despite the fact that they were unable to synthesize PGs. Thus, in some respects, the
lpg2
REV amastigotes resemble L. mexicana amastigotes. Future studies of the gene(s) responsible may shed
light on the mechanisms employed by L. major to survive in the absence of LPG2-dependent glycoconjugates
and may also improve the potential of the lpg2
 L. major line to serve as a live parasite vaccine by overcoming
its tendency to revert toward virulence.
Infections by the protozoan parasite Leishmania can cause
severe diseases in humans and animals, whose manifestations
range from mild cutaneous to fatal visceral pathology. Leish-
maniae are transmitted in the form of highly virulent metacy-
clic parasites, which develop inside the midgut of phleboto-
mine sand ﬂies and are inoculated into the mammalian host by
biting. Inside the acidiﬁed phagolysosome of host macro-
phages, leishmaniae differentiate into the aﬂagellate amasti-
gote stage, which resists leishmanicidal activities and inhibits
macrophage activation, processes that ultimately contribute to
amastigote survival and replication and disease pathology (8).
In most immunocompetent hosts, parasite growth and pathol-
ogy are eventually controlled by adaptive immune mechanisms
(2, 20), and the infection enters a chronic phase of parasite
persistence in the absence of signiﬁcant pathology. There are a
number of host factors which are known to modulate parasite
persistence and establish a delicate balance between gamma
interferon-induced leishmanicidal NO and immunesuppressive
interleukin-10 produced by CD25
 regulatory T cells (1, 2, 9,
25). In contrast, our knowledge concerning the identities and
roles of parasite factors which function differentially in medi-
ating persistence and in the acute pathogenic phase of infec-
tion is more limited.
Glycosylphosphatidyl inositol-anchored surface glycoconju-
gates, including lipophosphoglycan (LPG), glycoinositol phos-
pholipids (GIPLs), and proteins, such as proteophosphoglycan
(PPG) or gp63, form a dense glycocalyx in Leishmania. Many
of these compounds are important determinants of parasite
virulence, as shown by studies of puriﬁed molecules, as well as
mutants defective in the synthesis of one or more of the gly-
coconjugates (11, 12, 14, 22–24, 28). In Leishmania major, LPG
plays an important role in the establishment of infections in
macrophages following metacyclic invasion, while both GIPLs
and other alkylacyl phosphoglycerolipid moeities appear to
have small roles in macrophage survival despite their abun-
dance (12, 33). In contrast, parasite molecules that are depen-
dent on the activity of the LPG2-encoded Golgi GDP-man-
nose transporter, such as LPG and other phosphoglycans
(PGs) bearing the signature Gal-Man-P-based repeating unit,
are required for both initial establishment and subsequent
survival and replication of amastigotes within macrophages
(24). It should be emphasized that the ﬁndings described above
pertain to L. major and probably Leishmania donovani as well
(M. Wilson and S. M. Beverley, unpublished data). Remark-
ably, studies of Leishmania mexicana have suggested that this
species requires neither LPG, PGs, nor GIPLs for establish-
ment or replication within macrophages (7, 10). This difference
in reliance on highly abundant, structurally conserved mole-
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3622cules among Leishmania species was unanticipated and is not
well understood (4, 29).
Signiﬁcantly, the L. major lpg2
 parasite maintained the
ability to persist at the infection site in the absence of overt
pathology for more than 2 years (24). This ruled out the pos-
sibility that LPG2-dependent factors (such as PGs) are re-
quired in the persistent, asymptomatic phase of the disease. To
explain the fact that the lpg2
 parasite is unable to survive in
macrophages yet is able to survive indeﬁnitely in animals, we
suggested a model in which persistent parasites resided in
another, presumably more hospitable compartment within the
host, a compartment from which the parasite would be unable
to induce disease through perturbation of macrophage func-
tion. A corollary of this safe haven model is that parasites that
had recovered the ability to survive within macrophages would
similarly recover the ability to induce disease pathology. Here
we present evidence which supports this prediction and discuss
its relevance to Leishmania virulence and the use of live par-
asite-based immunization strategies.
MATERIALS AND METHODS
Parasite strains and culture. All parasites were derivatives of L. major strain
LV39 clone 5 (Rho/SU/59/P) and were cultivated in M199 medium (13). The lpg2
line obtained by homologous gene replacement (LPG2::HYG/LPG2::HYG)
has been described previously (24). P and P derivatives of this line (Fig. 1A)
were transfected with the construct pSNBR-LPG2 (B4831) and plated on semi-
solid M199 medium containing 20 g of G418 per ml.
Monoclonal antibodies, lectins, immunoﬂuorescence, and ﬂow cytometry.
Monoclonal antibody WIC79.3 recognizes L. major Gal-substituted Gal-Man-P
repeating units (6), and anti-trypanosomal tubulin antibody was provided by D.
Russell (Cornell University, Ithaca, N.Y.). Flow cytometry with ﬂuorescein-
conjugated ricin agglutinin (Sigma, St. Louis, Mo.) was performed with live
Leishmania. Parasites in the logarithmic growth phase (10
5 parasites/ml) were
washed twice in cold phosphate-buffered saline and incubated with 5 g ﬂuo-
rescein-conjugated ricin agglutinin per ml in phosphate-buffered saline for 10
min at 4°C. The analysis was performed with a Becton Dickinson FACS-Calibur
system (excitation wavelength, 488 nm; detection wavelength, 520 nm). Cells
were ﬁxed with 4% paraformaldehyde for 5 min at room temperature, perme-
abilized by incubation with ice-cold 100% ethanol for 15 min at 4°C, and se-
quentially incubated with monoclonal anti-PG antibody WIC79.3 (27) and ﬂu-
orescein isothiocyanate-conjugated anti-mouse immunoglobulin G. Parasites
were counterstained with polyclonal anti-tubulin and Texas Red-conjugated anti-
rabbit immunoglobulin G.
Mouse infection and limiting dilution assay. Virulence was assessed by using
6- to 8-week-old female BALB/c mice (Charles River Laboratories Inc., Wil-
mington, Mass.) following subcutaneous inoculation of 10
6 metacyclic parasites
into the hind footpads (26). The metacyclic parasites were isolated by density
centrifugation as described previously (21). Infections were monitored by com-
paring the thickness of the injected footpad to the thickness of the uninjected
footpad with a vernier caliper. Parasites in the infected tissue were enumerated
by a limiting dilution assay (26).
Macrophage infection. Starch-elicited peritoneal exudate macrophages (PEM)
from BALB/c mice were infected as described previously (22). Metacyclic par-
asites were opsonized by 30 min of incubation in Dulbecco modiﬁed Eagle
medium containing 4% C5-deﬁcient mouse serum (16) and were allowed to
invade macrophages in Dulbecco modiﬁed Eagle medium containing 0.7% bo-
vine serum albumin for2ha t3 3 °C at multiplicities of infection of 10 and 3
parasites per PEM for wild-type (WT) and lpg2 parasites, respectively. Amasti-
gotes were isolated from progressive lesions by tissue homogenization and dif-
ferential centrifugation, and PEM were infected for 2 h at 33°C at a ratio of three
parasites per PEM. Intracellular growth was determined by nuclear staining and
ﬂuorescence microscopy as described previously (22).
RESULTS
Emergence of an lpg2
 parasite population showing late
pathology. In previous studies performed in three different
laboratories, it was found that in most infections of susceptible
BALB/c mice with the lpg2
 null mutant, parasites were able
to persist indeﬁnitely without pathology (24, 30). In these ex-
periments, footpad inoculation was used to infect groups of
female BALB/c mice with 10
6 WT or lpg2
 metacyclic para-
sites that were isolated by Ficoll density centrifugation (21).
WT metacyclic parasites elicited lesions that appeared within
25 days (Fig. 1A), while in most experiments lpg2
 metacyclic
parasites failed to induce pathology, in agreement with previ-
ous ﬁndings (24). However, in two experiments involving in-
oculation with higher numbers of parasites, we observed that a
few mice developed lesions, which developed late (after 150 to
200 days) but progressed rapidly thereafter. For example, in
the experiment shown in Fig. 1A, three of eight of the lpg2

parasite-infected mice showed this same late-lesion proﬁle
(P mice), while the remaining mice showed no pathology, as
observed previously (24). The numbers of parasites were de-
termined by a limiting dilution assay (26) on day 346 postin-
fection, and the results showed that, as expected, infected mice
that did not exhibit overt pathology (mice 3-3, 4-3, 6-1, and 6-5)
contained a low level of persistent parasites (10
3 parasites)
(Fig. 1B). In contrast, in mice with the late-lesion pathology
(mice 4-4, 6-3, and 6-4), the numbers of parasites were nearly
10,000-fold higher (Fig. 1B).
The timing of lesion appearance differed from the timing
observed previously for LPG-deﬁcient lpg1
 L. major, which
requires LPG for establishment of a macrophage infection but
not for replication as amastigotes (22). Prompted by the sup-
position that this ﬁnding might reﬂect a new genetic difference
between the late-lesion lpg2
 parasites and the canonical per-
sistent lpg2
 parasites, we recovered parasites separately from
FIG. 1. Emergence of the lpg2
REV compensatory partial rever-
tant during mouse infection. (A) Lesion formation. A total of 10
6 WT
or lpg2
 metacyclic parasites were inoculated into groups of suscepti-
ble BALB/c mice, and the infections were monitored by comparing the
thickness of the injected footpad to the thickness of the uninjected
footpad with a vernier caliper. Inoculation of WT parasites resulted in
infections that appeared within 25 days (E), and, as shown previously,
ﬁve of eight mice infected with lpg2
 parasites showed no lesion
formation (P)( ). In contrast, three of eight mice infected with
lpg2
 parasites in this experiment showed lesion formation beginning
around day 125 (P)( ); the parasites in these mice were designated
lpg2
REV parasites. The bars indicate the standard deviations for WT
parasites (n  4), P lpg2
 parasites (n  5), and P lpg2
 parasites
(n  3). (B) Limiting dilution assay. Representative P or P mice
from the experiment shown in panel A were sacriﬁced on day 346
postinfection, and the numbers of parasites in the infected footpads
were determined by limiting dilution. The lesion sizes (upper panel)
and the parasite burdens (lower panel) of individual animals are indi-
cated.
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and mice which had lesions (designated P) (Fig. 1A).
Late-pathology lpg2
 P parasites do not make PGs in the
promastigote form. Following recovery, the two populations of
parasites were allowed to differentiate into promastigotes in
vitro, and PG expression was analyzed by examining reactivity
with anti-PG antibody WIC79.3 in a Western blot analysis (Fig.
2A) and by ﬂow cytometry with the -Gal-binding lectin ricin
agglutinin (Fig. 2B). WT promastigotes expressed an abun-
dance of LPG and PPG, as shown by Western blotting, while
the lpg1
 mutant (defective in LPG core synthesis) showed the
expected synthesis of PPG but did not express LPG (Fig. 2A).
Importantly, the lpg2
 P and P populations maintained the
total PG-deﬁcient phenotype expected for the lpg2
 promasti-
gotes, showing that they were neither WT contaminants nor
second-site revertants that exhibited restored promastigote PG
synthesis. It should be emphasized that the LPG2 coding re-
gion had been removed completely from the lpg2
 line by
homologous gene replacement (24), and thus reconstitution of
LPG2 itself was impossible. Interestingly, inspection of the
available L. major genome sequence data revealed the pres-
ence of several members of the nucleotide sugar transporter
family whose functions are unknown, in addition to the antic-
ipated UDP-Gal transporters (A. Capul and S. M. Beverley,
unpublished data). However, activation of an alternative GDP-
Man transport activity in P lpg2
 promastigotes was ruled
out by these data.
P and P lpg2
 parasites breed true. When 10
6 metacyclic
parasites were inoculated into mice, the P lpg2
 parasites
yielded persistent infections similar to those seen previously; as
in previous studies, no infected mouse went on to develop
lesions or pathology over a 1-year period (Fig. 3A and data not
shown). Notably, restoration of LPG2 expression restored PG
FIG. 2. Characterization of P and P lpg2
 promastigotes. (A) Western blot analysis. Promastigotes from WT, lpg1
, and lpg2
 P and P
populations were subjected to Western blot analysis with the anti-PG antibody WIC79.3 (6). The positions of WT PPG and LPG are shown. (B) PG
ﬂow cytometry. A total of 10
5 promastigotes from a logarithmic culture were incubated with ricin-ﬂuorescein isothiocyanate (FITC) at 4°C prior
to analysis. (Upper panel) WT and lpg2
 P parasites; (lower panel) lpg2
 P parasites. The parental lpg2
 population was indistinguishable from
the P and P populations (data not shown).
FIG. 3. P lpg2
 population breeds true. (A and B) Mouse infec-
tions. A total of 10
6 puriﬁed WT (} and ), lpg2
 (), or lpg2
 P
() metacyclic parasites were inoculated into the footpads of BALB/c
mice, and lesion formation was monitored. Each point indicates the
average for three mice inoculated with WT parasites or ﬁve mice
inoculated with lpg2
 or lpg2
 P parasites; the error bars indicate
standard deviations. (C and D) Restoration of LPG2 expression fully
restores surface LPG expression in P and P lpg2
 lines. LPG expres-
sion in promastigotes of WT parasites (solid proﬁle) and the lpg2

(P)/ LPG2 (panel C, open proﬁle) or lpg2
 (P)/ LPG2 addback
lines was assessed by ﬂow cytometry with ﬂuorescent ricin as described
in Materials and Methods. As shown previously, the dominant PG
detected by this assay is LPG (22). FITC, ﬂuorescein isothiocyanate.
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levels (Fig. 3A). These results demonstrated that the P lpg2

parasites were not generally and irreversibly avirulent, a potential
concern since loss of virulence occurs sporadically during long-
term culture or genetic manipulation of Leishmania in vitro (5).
Thus, the Plpg2
 parasites appear to be identical to the original
lpg2
 population described previously (24).
In contrast, the P lpg2
 parasites produced lesions in every
infected mouse, again with a delay of 125 days (Fig. 3B). This
showed that the late-lesion or P phenotype was a stable trait,
and we designated this population lpg2
REV.A si nt h elpg2

parental line, reexpression of LPG2 in the lpg2
REV popula-
tion restored LPG and PG synthesis (Fig. 3D).
lpg2
REV parasites survive in macrophages in the amasti-
gote form but not in the promastigote form. Infection of mouse
macrophages with lpg2
 (P)o rlpg2
REV (P) metacyclic
parasites showed that neither survived, as observed previously
(24; data not shown). While lpg2
 (P) amastigotes could not
be obtained, we were able to recover amastigotes from mouse
lesions obtained with lpg2
REV parasites (obtained around
day 150). The lpg2
REV amastigotes were capable of surviving
and replicating well in macrophages, although the growth rate
was about twofold lower than that of WT amastigotes (Fig.
4B). The size of the lpg2
REV parasitophorous vacuole was
similar to that seen in other L. major infections, and the vac-
uole was not extended like that seen in L. mexicana infections
(Fig. 4A).
lpg2
REV parasites do not make PGs. As described above
for promastigotes, it was possible that the lpg2
REV amasti-
gotes had recovered the ability to synthesize PGs through
activation of an amastigote-speciﬁc pathway that restored
Golgi GDP-Man uptake. In WT amastigotes, PGs predomi-
nantly localized to the parasite cytoplasm and accumulated in
a vesicular compartment, most likely the ﬂagellar pocket, as
expected for secreted PGs (Fig. 4A, left panels). However,
immunoﬂuorescence analysis of the infected macrophages with
anti-PG antisera showed that the lpg2
REV amastigotes failed
to synthesize detectable levels of PGs, and only background
ﬂuorescence was evident (Fig. 4A, right panels). These data
eliminated the possibility that there was activation of an alter-
native amastigote Golgi GDP-Man transport activity in this
line.
DISCUSSION
In previous studies it was shown that LPG was important for
the ability of L. major to establish infections in macrophages,
while LPG2-dependent molecules, such as LPG and related
PGs, were required for replication of parasites within macro-
phages in the amastigote form and subsequent pathology (24).
The lpg2
 parasites used in these studies failed to induce any
pathology in mice, although they were able to persist indeﬁ-
nitely in the absence of overt lesion formation. In this study we
characterized a variant of the lpg2 line designated the
lpg2
REV line, which is able to reproducibly produce pathol-
ogy in mice, albeit after a considerable delay (Fig. 1A). Nota-
bly, neither promastigote nor amastigote forms of the
lpg2
REV parasite regained the ability to synthesize PGs, and
thus this mutant did not arise through activation of an alter-
native Golgi GDP-Man transporter activity.
FIG. 4. lpg2
REV parasites replicate in macrophages but do not
synthesize PGs. (A) Immunoﬂuorescence analysis of amastigote PGs.
PEM were infected with WT and lpg2
REV amastigote parasites and
stained 2 days postinfection for reactivity with tubulin or PGs as de-
scribed in Materials and Methods. Bar  10 m. (B) Macrophage
replication. Murine macrophages were infected with WT (E)o r
lpg2
REV () amastigotes as described in Materials and Methods, and
the numbers of parasites were determined and normalized to the initial
infection obtained at 2 h (day zero). The values are averages and
standard deviations for a representative experiment performed in trip-
licate.
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by the lpg2
REV parasite is characteristic of mutants with
mutations that affect the ability of Leishmania to establish
infections in macrophages (e.g., to enter, survive, and differ-
entiate) but not the ability to replicate in the amastigote form.
This may be due to defects in macrophage survival (as ob-
served previously with LPG-deﬁcient LPG1 null mutants or
ether phospholipid-deﬁcient ADS1 null mutants [22, 33]) or to
differentiation to form the infectious metacyclic stage (as ob-
served in sphingolipid synthetic mutants [32; unpublished
data]). Consistent with this notion, lpg2
REV parasites were
poorly infective in macrophages in the promastigote form,
reﬂecting the absence of PGs, such as LPG. However, in strik-
ing contrast to the amastigote form of the lpg2
 parent,
lpg2
REV amastigotes showed good survival and replication in
macrophages (Fig. 4B). Thus, these parasites in some manner
acquired a compensatory mutation that enables amastigote
replication in the absence of PGs or perhaps other molecules
dependent on the activity of LPG2.
The following hypothetical scenario accounts for the emer-
gence and properties of the lpg2
REV parasites (Fig. 5A) (24).
As shown previously, in a normal infection with metacyclic
promastigotes most lpg2
 parasites were phagocytosed by mac-
rophages and destroyed, while a small proportion of the par-
asites escaped, possibly by residing in a cell type other than
macrophages that lacked leishmanicidal potential (3, 22). In
this presumptive safe haven the lpg2
 parasites were able to
persist indeﬁnitely (700 days) at low levels (1,000 para-
sites). Little is known about the parasites during this stage,
including their differentiation state or whether they replicate.
One possibility is that the persistent parasites slowly turn over
and constantly leave their safe haven, where they are then
challenged by host macrophages. This possibility is consistent
with the role of negative host factors, such as NO, which
mediate parasite killing by macrophages, thereby keeping per-
sistent Leishmania infections in check (25). For the lpg2
 par-
asites, entry into macrophages would lead to destruction until
the emergence of variant cells that had acquired the ability to
survive and replicate in macrophages, such as lpg2
REV cells,
which ultimately would lead to disease pathology. Since the
lpg2
REV parasites did not regain the ability to synthesize
LPG or PGs, they remained attenuated in the ability to estab-
lish macrophage infections initially in the promastigote form,
as observed here. This model makes several testable predic-
tions regarding the nature of the host cell phenotype, its leish-
manicidal potential, and the interaction with the host immune
system. However, validating these predictions requires identi-
ﬁcation of the persistent lpg2
 parasite population, a challeng-
ing task which is currently under way.
The emergence of the lpg2
REV phenotype is relevant to
the development of live vaccines in which the lpg2
 parasite is
used (30). To date, numerous protocols in which recombinant
leishmanial antigens or heat-killed Leishmania have been used
have failed to induce long-lasting immunity (15, 18, 19). In
contrast, long-term protection is achieved following recovery
from a natural infection, suggesting that parasite persistence is
a prerequisite for sterile immunity (2, 31). lpg2
 parasites
fulﬁll the major requirements for a live vaccine candidate (i.e.,
persistent infection in the absence of disease), and vaccination
studies with BALB/c mice and lpg2
 parasites indeed induced
dramatic protection against virulent challenge in the absence
of a strong Th1 response (30). An interesting question for
future study is the contribution of the host immune response to
the delayed emergence of lpg2
REV parasite infections and
whether this may provide some further perspective on the
nature of the immune response to lpg2
 parasites. Regardless,
it is very clear the lpg2
REV phenotype compromises the po-
tential utility of the lpg2
 line as a vaccine candidate, and thus
preventing its occurrence is important.
In contrast to L. major, L. mexicana does not require PGs for
virulence or amastigote replication, implying that there are
FIG. 5. Summary of comparisons of lpg2
REV L. major. In both
panels, the known role of LPG2 is in transport of GDP-mannose into
the parasite Golgi apparatus, where it is utilized for the synthesis of
PGs of various forms. (A) Proposed working model for pathology and
persistence of WT parasites (upper panel) and lpg2
 or lpg2
REV L.
major parasites (lower panel) in mouse infections. See Discussion for
more information. This ﬁgure is modiﬁed from that presented by Sp´ ¨th
et al. (24). (B) L. major lpg2
REV parasites have a PG dependence
phenotype intermediate between those of WT L. mexicana and L.
major. See Discussion for more information. M	, macrophage.
3626 SPA ¨TH ET AL. INFECT.I MMUN.PG-independent mechanisms of macrophage survival (7, 10).
In a recent review the possibility that different Leishmania
species placed different levels of emphasis during evolution on
the use of surface glycoconjugates for intracellular survival was
discussed (29). The differences among the species are summa-
rized in Fig. 5B, which shows that L. major requires LPG2-
dependent glycoconjugates, such as LPG and/or PGs, for es-
tablishment of macrophage infections by promastigotes, as well
as for survival and induction of pathology by amastigotes, while
L. mexicana does not. Interestingly, the L. major lpg2
REV
line exhibits intermediate behavior; it is deﬁcient in the ability
to establish macrophage infections without PGs, like L. major,
but it retains the ability to survive and replicate in the amas-
tigote form without PGs, like L. mexicana. It is tempting to
speculate that the gene(s) or pathway(s) altered in the L. major
lpg2
REV line is related to the pathways that enable L. mexi-
cana to replicate in macrophages in the absence of PGs. Some
interesting glycoconjugates recently implicated in amastigote
virulence in L. mexicana are the 1-2 mannans, which are also
found in L. major (17; unpublished data). However, the cyto-
plasmic location of mannans makes it unlikely that their syn-
thesis is LPG2 dependent (17).
It may be possible to exploit the differences between the L.
major lpg2
 and lpg2
REV lines identiﬁed in this study in
genetic strategies to identify the relevant genes responsible.
Thus, the lpg2
REV line provides a unique tool that may
facilitate studies to gain important insight into mechanisms of
vaccination and virulence.
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